Authors: Rebecca Caeser, Jacklynn V. Egger, Shweta Chavan, Nicholas D. Socci, Caitlin Byrne Jones, Faruk Erdem Kombak, Marina Asher, Michael H. Roehrl, Nisargbhai S. Shah, Viola Allaj, Parvathy Manoj, Sam E. Tischfield, Amanda Kulick, Maximiliano Meneses, Christine A. Iacobuzio-Donahue, W. Victoria Lai, Umeshkumar Bhanot, Marina K. Baine, Natasha Rekhtman, Travis J. Hollmann, Elisa de Stanchina, John T. Poirier, Charles M. Rudin, Triparna Sen
Published: 2022-04-19
DOI: 10.1038/s41467-022-29794-4
Source: Full article
AbstractAccess to clinically relevant small cell lung cancer (SCLC) tissue is limited because surgical resection is rare in metastatic SCLC. Patient-derived xenografts (PDX) and circulating tumor cell-derived xenografts (CDX) have emerged as valuable tools to characterize SCLC. Here, we present a resource of 46 extensively annotated PDX/CDX models derived from 33 patients with SCLC. We perform multi-omic analyses, using targeted tumor next-generation sequencing, RNA-sequencing, and immunohistochemistry to deconvolute the mutational landscapes, global expression profiles, and molecular subtypes of these SCLC models. SCLC subtypes characterized by transcriptional regulators, ASCL1, NEUROD1 and POU2F3 are confirmed in this cohort. A subset of SCLC clinical specimens, including matched PDX/CDX and clinical specimen pairs, confirm that the primary features and genomic and proteomic landscapes of the tumors of origin are preserved in the derivative PDX models. This resource provides a powerful system to study SCLC biology.